Archive | Biopharmaceuticals

Global “Risk-On” Rally Across Most Sectors Especially Biotechnology

prednisone 10mg buy The Bi-Partisan Cliff Deal Nobody Likes (Except the Market) Investors like the tax deal as it is favorable to investors despite the tax increases. Stocks are holding their gains after a “mini-fiscal” cliff deal that drove the Dow and S&P up 1.7% and NASDAQ up 2.4%. Life science stocks soared as they usually trade with the […]

Continue Reading 0

Rayno Biopharmaceutical Focus Stocks YTD: Top Performers include AMRI,GILD, REGN

http://websolutionx.com/wp-cron.php?doing_wp_cron=1532825589.5472540855407714843750 Outstanding Year for Biotechnology -Average Performance is up 35% YTD Many Rayno Life Science Stocks have outperformed the sector and the ETFs: Albany Molecular Inc. (AMRI), a contract research organization with long term experience in drug discovery, development and manufacturing soared 82% YTD on improved financial results.The stock is a turnaround story and is still […]

Continue Reading 0

Another Stealth Rally In Biopharmaceuticals: AMGN IBB REGN VPHM

http://oostrum.biz/wp-json/oembed/1.0/embed?url=http://oostrum.biz/ Rayno Life Science Stocks Move Higher Biotech stocks are ignoring the volatility from the political fray today with big moves in many Rayno Life Science stocks and a 1.5% move in the bellwether ETF (IBB).The tech heavy QQQ lagged up only 0.7%. Overall, despite the negative comments on the fiscal cliff negotiations the market believes […]

Continue Reading 0

Rayno Life Science Mid-day Movers: AMRI, ASTX, CPHD, ILMN, REGN

Markets Are Back To Fretting About Fiscal Cliff Bernanke scolded Congress on the fiscal cliff and markets turned down. Despite a lackluster market down about 0.3% there is a lot of green in biotech. Among the winners in the Rayno Life Science universe are: Albany Molecular (AMRI $4.21) broke through to new highs up 43% YTD. […]

Continue Reading 0

Raygent Biopharmaceutical Portfolio: Celgene (CELG) and Gilead (GILD) Ignite Rally

buy cheap tetracycline A languishing biotech sector rallied today with clinical news with Hepatitis C (HCV) drugs. The Rayno Biopharma Portfolio was up 2.4% led by Gilead Sciences (GILD) up 11.5%, Regeneron (REGN) up 3.3% and ViroPharma (VPHM) up 3.2%. Gilead shares were up $7.50 on favorable Phase 2 results with their antiviral drug GS-5885 in combination with ribavirin. […]

Continue Reading 0

Rayno Life Science: Biotechnology Sector Should Find Support Today

Trends from early trading show promise for intermediate support in larger cap biotech shares today with the NASDAQ up 0.5% in early trading. This could be a good day for covering shorts and re-balancing in anticipation for a Q4 rally : The IBB (130.82) is up 1.88%. The XBI is up 2.37%. MO stocks are […]

Continue Reading 0

Sell-Off Continues in Biotechnology Sector: Down 2% With High Fliers Down More

Huge Profits YTD Bring Selling-Momentum is Broken Profit taking has hit the biotechnology sector again today with major ETFs down 2% and momentum stocks hit harder. We recommended caution on 10/22 (see below) as momentum eased on stocks that were up over 100% YTD with the overall sector up 40%. Despite recent media coverage of […]

Continue Reading 0

NASDAQ Correction Hits Biotechnology Stocks: Update 1 10/24

Biotech At Risk: Take a Little Off Speculative Stocks Biotechnology remains one of the strongest sectors of 2012 especially earnings driven, large cap stocks all doing well today: Amgen (AMGN $88.4) up 1%, Biogen (BIIB $142.6) up 0.4% and  Gilead (GILD $68.85) up 6%. Biogen Idec earnings are due tomorrow. See summary below of 2012 […]

Continue Reading 0

Rayno Life Science Portfolios: Biotechnology Stocks Should Outperform in Q4

Good Day for Biotech with a Strong Appetite for Two IPOs in A Choppy Market Intercept Pharmaceuticals (ICPT) was up 29.33% to $19.40 on a public offering of 5M shares at $15 raising $75M. The Company is developing clinical stage therapeutics to treat chronic liver diseases. BofA MerrillLynch is acting as sole book running manager with […]

Continue Reading 0

Rayno Life Science Portfolio Biopharmaceuticals: ALXN, GILD, REGN, SGEN

Biotechnology Sector Continues Amazing Bull Run Up 40% YTD The Rayno Life Science Portfolio had nice gains today with 1% + moves from Biogen-Idec (BIIB) and Gilead Sciences (GILD) and with our bellwether ETF (IBB) eking out a 0.5% gain at its 52 week high. Since the bull market began in February 2009 several stocks […]

Continue Reading 0